iCAD, Inc. (NASDAQ:ICAD - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.54 and traded as high as $2.42. iCAD shares last traded at $2.34, with a volume of 484,462 shares.
Wall Street Analysts Forecast Growth
Separately, StockNews.com downgraded shares of iCAD from a "hold" rating to a "sell" rating in a report on Wednesday.
Check Out Our Latest Research Report on ICAD
iCAD Trading Down 23.7 %
The stock's fifty day moving average is $1.70 and its two-hundred day moving average is $1.54. The company has a market capitalization of $47.37 million, a PE ratio of -16.91 and a beta of 1.47.
iCAD (NASDAQ:ICAD - Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The technology company reported ($0.07) earnings per share (EPS) for the quarter. iCAD had a negative net margin of 15.67% and a negative return on equity of 13.59%. The firm had revenue of $5.03 million during the quarter.
Institutional Investors Weigh In On iCAD
Several hedge funds and other institutional investors have recently modified their holdings of ICAD. Virtu Financial LLC boosted its stake in shares of iCAD by 55.6% during the first quarter. Virtu Financial LLC now owns 21,286 shares of the technology company's stock valued at $34,000 after purchasing an additional 7,604 shares during the period. Perritt Capital Management Inc boosted its position in iCAD by 14.2% in the second quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company's stock worth $208,000 after purchasing an additional 19,917 shares during the last quarter. Essex LLC purchased a new position in shares of iCAD during the 3rd quarter valued at about $216,000. Perritt Capital Management Inc. raised its stake in iCAD by 7.5% during the 1st quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company's stock valued at $225,000 after purchasing an additional 9,717 shares during the period. Finally, First Eagle Investment Management LLC raised its stake in iCAD by 3.2% during the 1st quarter. First Eagle Investment Management LLC now owns 701,525 shares of the technology company's stock valued at $1,129,000 after purchasing an additional 22,000 shares during the period. 24.61% of the stock is currently owned by institutional investors.
iCAD Company Profile
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
See Also
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
